Home › Procedures › MRI Pelvis › Aetna
📋

Aetna — MRI Pelvis

This page shows prior authorization criteria extracted from Aetna's published imaging guidelines. 166 matching coverage rules found for this procedure.

Coverage Rules from Aetna Policy

Abdominal Pain

Indication Code: AB-2.2

Abdominal Wall Mass

Indication Code: PEDAB-13.1

Abnormal Findings on Endoscopy/Colonoscopy

Indication Code: AB-13.3

Abnormal Uterine Bleeding

Indication Code: PEDPV-2.1

Abscess

Indication Code: PV-21.2

Adenomyosis

Indication Code: PV-4.1

Adrenal Hormone Excess/Symptomatic Adrenal Lesions

Indication Code: AB-16.2

Adrenal Tumors – Initial Work-up/Staging

Indication Code: ONC-15.10

Adrenal Tumors – Restaging/Recurrence

Indication Code: ONC-15.11

Adrenal Tumors – Surveillance

Indication Code: ONC-15.12

Adrenocortical Carcinoma

Indication Code: ONC-15.13

Amenorrhea

Indication Code: PEDPV-4.1

Anal Carcinoma – Initial Work-up/Staging

Indication Code: ONC-24.2

Anal Carcinoma – Restaging/Recurrence

Indication Code: ONC-24.3

Anal Carcinoma – Surveillance

Indication Code: ONC-24.4

Asymptomatic Hematuria

Indication Code: AB-39.2

Bilateral Wilms Tumor (BWT)

Indication Code: PEDONC-7.3

Bowel Obstruction

Indication Code: PEDAB-28.1

Bowel Obstruction

Indication Code: AB-20.1

Bronchopulmonary or Thymic Carcinoid – Initial Staging

Indication Code: ONC-15.6

Bronchopulmonary or Thymic Carcinoid – Restaging/Recurrence

Indication Code: ONC-15.7

Bronchopulmonary or Thymic Carcinoid – Surveillance

Indication Code: ONC-15.8

C-section, Cornual or Interstitial Ectopic Pregnancy

Indication Code: PV-15.3

Cancers of External Genitalia – Initial Work-Up/Staging

Indication Code: ONC-24.6

Cancers of External Genitalia – Restaging/Recurrence

Indication Code: ONC-24.7

Celiac Disease

Indication Code: AB-24.1

Cervical Cancer – Initial Work-Up/Staging

Indication Code: ONC-23.2

Cervical Cancer – Restaging/Recurrence

Indication Code: ONC-23.3

Cervical Cancer – Surveillance

Indication Code: ONC-23.4

CHF – Imaging

Indication Code: CD-9.1

Chronic Diarrhea (More than 30 Days)

Indication Code: AB-21.2

Classical Hodgkin Lymphoma

Indication Code: ONC-28.2

Clear Cell Sarcoma of the Kidney (CCSK)

Indication Code: PEDONC-7.5

Coccydynia without Neurological Features

Indication Code: SP-5.2

Colorectal Cancer – Initial Work-up/Staging

Indication Code: ONC-16.2

Colorectal Cancer – Restaging/Recurrence

Indication Code: ONC-16.3

Colorectal Cancer – Surveillance/Follow-up

Indication Code: ONC-16.4

Complex Adnexal Masses

Indication Code: PV-5.3

Congenital Mesoblastic Nephroma (CMN)

Indication Code: PEDONC-7.7

Constipation

Indication Code: AB-21.3

Constipation, Diarrhea, and Irritable Bowel Syndrome

Indication Code: PEDAB-12

Constipation, Diarrhea, and Irritable Bowel Syndrome

Indication Code: PEDAB-12

Endometriosis

Indication Code: PV-6.1

Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors

Indication Code: ONC-31.8

Familial Adenomatous Polyposis (FAP) and Related Conditions

Indication Code: PEDONC-2.7

Fecal Incontinence

Indication Code: PV-22.4

Fetal MRI

Indication Code: PV-15.1

Fistula in Ano

Indication Code: PV-21.1

Fistulae

Indication Code: AB-48

Fistulae

Indication Code: AB-48

Flank Pain, Renal Stone

Indication Code: PEDAB-4

Flank Pain, Renal Stone

Indication Code: PEDAB-4

Focal Neuropathy

Indication Code: PN-2.1

Gallbladder and Biliary Tumors – Initial Work-up/Staging

Indication Code: ONC-14.6

Gallbladder and Biliary Tumors – Restaging/Recurrence

Indication Code: ONC-14.7

Gallbladder and Biliary Tumors – Surveillance/Follow-up

Indication Code: ONC-14.8

Gastric Cancer – Surveillance/Follow-up

Indication Code: ONC-14.11

Gastrointestinal Stromal Tumor (GIST)

Indication Code: ONC-12.5

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Initial Work-up/Staging

Indication Code: ONC-15.3

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Restaging/Recurrence

Indication Code: ONC-15.4

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Surveillance

Indication Code: ONC-15.5

Gastrointestinal/Pancreatic Neuroendocrine Cancers – Suspected/Diagnosis

Indication Code: ONC-15.2

Gender Affirmation Surgery; Pelvic

Indication Code: PV-26.1

General Guidelines – Overview

Indication Code: PV-1.1

General Pain

Indication Code: MS-32.1

GI Bleeding

Indication Code: AB-22.1

Hemophagocytic Lymphohistiocytosis (HLH)

Indication Code: PEDONC-18.3

Hepatoblastoma

Indication Code: PEDONC-11.2

Hepatocellular Carcinoma (HCC) – Initial Work-up/Staging

Indication Code: ONC-14.3

Hepatocellular Carcinoma (HCC) – Restaging/Recurrence

Indication Code: ONC-14.4

Hepatocellular Carcinoma (HCC) – Surveillance/Follow-up

Indication Code: ONC-14.5

Hereditary Paraganglioma-Pheochromocytoma (HPP) Syndromes

Indication Code: PEDONC-2.13

Hydronephrosis

Indication Code: PEDAB-20

Hydronephrosis

Indication Code: PEDAB-20

Impotence/Erectile Dysfunction

Indication Code: PV-17.1

Incontinence

Indication Code: PEDPV-14.1

Indeterminate Intra-Abdominal Mass

Indication Code: AB-13.2

Inflammatory Bowel Disease, Crohn Disease, or Ulcerative Colitis

Indication Code: PEDAB-9

Inflammatory Bowel Disease, Crohn Disease, or Ulcerative Colitis

Indication Code: PEDAB-9

Inflammatory Spondylitis

Indication Code: SP-10.2

Inguinal or Femoral Hernia, or Indeterminate Groin Pain

Indication Code: AB-12.1

Intrauterine Device

Indication Code: PV-10.1

Joint Instability and Dysfunction

Indication Code: MS-30.1

Known IBD

Indication Code: AB-23.2

Leiomyoma/Uterine Fibroids

Indication Code: PV-12.1

Lower Urinary Tract Infection

Indication Code: AB-40.2

Lumbar and Lumbosacral Plexus

Indication Code: PN-5.1

LUMBAR Syndrome

Indication Code: PEDPVD-5.4

Male Pelvic Disorders

Indication Code: PV-19.1

Malignant Rhabdoid Tumor of the Kidney (MRT) and Other Extracranial Sites

Indication Code: PEDONC-7.6

MR Enterography and Enteroclysis Coding Notes

Indication Code: AB-1.4

Muscle and Tendon Injuries

Indication Code: MS-11.1

Neuroblastoma – Initial Staging

Indication Code: PEDONC-6.3

Neuroblastoma – Surveillance Imaging (Risk Group Dependent)

Indication Code: PEDONC-6.5

Neuroblastoma – Treatment Response Imaging (Risk Group Dependent)

Indication Code: PEDONC-6.4

Neuromuscular Junction Disorders

Indication Code: PN-8.4

Non-Cutaneous Indications to Suspect Occult Spinal Dysraphism

Indication Code: PEDSP-4.3

Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Indication Code: PEDONC-8.3

Ocular Melanoma

Indication Code: ONC-5.9

Other Renal Cell Cancer Predisposition Syndromes

Indication Code: PEDONC-2.17

Ovarian Cancer – Initial Work-Up/Staging

Indication Code: ONC-21.3

Ovarian Cancer – Restaging/Recurrence

Indication Code: ONC-21.4

Ovarian Cancer – Surveillance

Indication Code: ONC-21.5

Ovarian Cancer – Suspected/Diagnosis

Indication Code: ONC-21.2

Pancreatic Cancer – Surveillance/Follow-up

Indication Code: ONC-13.5

Paraneoplastic Syndromes

Indication Code: ONC-30.3

Paratesticular and spermatic cord masses

Indication Code: PV-20.2

Patent Urachus

Indication Code: PV-23.1

Patent Urachus

Indication Code: PEDPV-15.1

Pediatric Aggressive Mature B-Cell Non-Hodgkin Lymphomas (NHL)

Indication Code: PEDONC-5.3

Pediatric Germ Cell Tumors

Indication Code: PEDONC-10

Pediatric Germ Cell Tumors

Indication Code: PEDONC-10

Pediatric Hepatocellular Carcinoma (HCC)

Indication Code: PEDONC-11.3

Pediatric Hodgkin Lymphoma (HL)

Indication Code: PEDONC-5.2

Pediatric Pancreatic Carcinoma

Indication Code: PEDONC-11.4

Pediatric Pelvis Imaging Modality General Considerations

Indication Code: PEDPV-1.3

Pediatric Renal Cell Carcinoma (RCC)

Indication Code: PEDONC-7.4

Pelvic Fistula

Indication Code: PV-21.3

Pelvic Inflammatory Disease

Indication Code: PV-7.1

Pelvic Inflammatory Disease (PID)

Indication Code: PEDPV-3.1

Pelvic Pain/Dyspareunia, Female

Indication Code: PV-11.1

Pelvic Prolapse

Indication Code: PV-22.3

Penis-Soft Tissue Mass

Indication Code: PV-18.1

Perirectal/Perianal Crohn's Disease

Indication Code: AB-23.3

Periurethral cysts, Skene duct cyst, Bartholin's gland cysts and Gartner’s duct cyst

Indication Code: PV-13.1

Placenta Accreta/Placenta Accreta Spectrum/Placenta Percreta

Indication Code: PV-15.2

Post-Transplant Imaging

Indication Code: PEDONC-20.2

Postoperative Pain within 60 Days Following Abdominal Surgery

Indication Code: PEDAB-11

Postoperative Pain within 60 Days Following Abdominal Surgery

Indication Code: PEDAB-11

Prostate Cancer – Follow-up On Active Surveillance

Indication Code: ONC-19.4

Prostate Cancer – Initial Work-up/Staging

Indication Code: ONC-19.2

Prostate Cancer – Restaging/Recurrence

Indication Code: ONC-19.3

Pyelonephritis

Indication Code: AB-40.1

Renal Cell Cancer (RCC) – Surveillance

Indication Code: ONC-17.4

Retained Products of Conception

Indication Code: PV-2.2

Retinoblastoma – Imaging

Indication Code: PEDONC-12.2

Retroperitoneal Fibrosis

Indication Code: AB-47.0

Right Lower Quadrant Pain

Indication Code: PEDAB-3

Right Lower Quadrant Pain

Indication Code: PEDAB-3

Sacro-Iliac (SI) Joint Pain/Sacroiliitis

Indication Code: SP-10.1

Scrotal Pathology

Indication Code: PV-20.1

Scrotal Pathology

Indication Code: PEDPV-12.1

Secondary Amenorrhea

Indication Code: PV-3.1

Small Bowel Bleeding Suspected

Indication Code: AB-22.2

Small Bowel Cancer – Initial Work-up/Staging

Indication Code: ONC-16.5

Soft Tissue Sarcomas – Initial Work-up/Staging

Indication Code: ONC-12.2

Spinal Dysraphism

Indication Code: PEDSP-4.4

Suspected Adnexal Mass – Initial Evaluation

Indication Code: PV-5.1

Suspected IBD (Crohn’s Disease or Ulcerative Colitis)

Indication Code: AB-23.1

Suspected Prostate Cancer

Indication Code: ONC-19.1

Suspected Renal/Ureteral Stone(s)

Indication Code: AB-4.1

Testicular, Ovarian and Extragonadal Germ Cell Tumors – General Considerations

Indication Code: ONC-20.0

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Initial Work-Up/Staging

Indication Code: ONC-20.1

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Restaging/Recurrence

Indication Code: ONC-20.2

Testicular, Ovarian and Extragonadal Germ Cell Tumors – Surveillance

Indication Code: ONC-20.3

Transitional Cell Cancer – Initial Work-up/Staging

Indication Code: ONC-18.2

Transitional Cell Cancer – Surveillance/Follow-up

Indication Code: ONC-18.4

Undescended Testis

Indication Code: PEDPV-11.1

Unilateral Wilms Tumor (UWT)

Indication Code: PEDONC-7.2

Upper Urinary Tract

Indication Code: PEDAB-5.1

Urethral Diverticula

Indication Code: PV-13.2

Uterine Anomalies

Indication Code: PV-14.1

Uterine Cancer – Initial Work-Up/Staging

Indication Code: ONC-22.2

Uterine Cancer – Restaging/Recurrence

Indication Code: ONC-22.3

Vaginal Anomalies

Indication Code: PV-14.2

Vaginal Masses

Indication Code: PV-13.3

How to Submit a Prior Authorization Request

Submit via: Aetna Provider Portal (provider.aetna.com) or eviCore at 1-800-252-2021

📄 Required Documentation Checklist

  • Patient demographics and insurance information
  • Ordering provider NPI and contact information
  • Specific clinical indication with ICD-10 diagnosis code(s)
  • Relevant clinical history and physical exam findings
  • Results of prior conservative treatment (if applicable)
  • Prior imaging results relevant to the indication
  • Supporting lab or diagnostic results where applicable

⏱ Turnaround Times

Standard prior authorization requests are typically processed within 3–5 business days. Urgent/expedited requests may be processed within 24–72 hours when clinically necessary.

📣 Appeal Window

Most plans allow 30–60 days to file a first-level appeal. Expedited appeals for urgent cases are typically processed within 72 hours.

⚠ Common Denial Reasons

  • Insufficient clinical documentation to establish medical necessity
  • Clinical criteria not met per payer guidelines
  • Lack of documented prior conservative treatment
  • Missing required prior imaging as step therapy
  • Incorrect or unsupported ICD-10 diagnosis code pairing
  • Request submitted outside of authorization timeframe

⚠ MRI uses no ionizing radiation, which is an important clinical consideration when choosing between MRI and CT.

Clinical Approval Criteria

✓ Generally Approved When:

  • Reference prior ultrasound results
  • Fibroid mapping: document planned procedure (myomectomy, UFE) and that MRI will guide it
  • Prostate MRI: document PSA level, prior biopsy results, and clinical staging question
← Back to MRI Pelvis overview Search Coverage Database →
Disclaimer: Coverage criteria shown on this page are sourced from publicly available payer guidelines and are provided for informational and educational purposes only. Prior authorization requirements change frequently. Always verify current criteria directly with the payer or their delegated utilization management company before submitting an authorization request. This page does not constitute medical or legal advice.